Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study

Theresa H Keegan, Sally L. Glaser, Christina A. Clarke, Margaret L. Gulley, Fiona E. Craig, Joseph A. DiGiuseppe, Ronald F. Dorfman, Risa B. Mann, Richard F. Ambinder

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Purpose: Epstein-Barr virus (EBV) in Hodgkin's lymphoma (HL) cells has been considered as a prognostic marker for this heterogeneous disease, but studies have yielded mixed findings, likely because of selected patient series and failure to acknowledge an effect of age on outcome. This study assessed survival after HL in a population-based cohort large enough to examine the joint effects of EBV with other factors including age, sex, and histologic subtype. Patients and Methods: Included were 922 patients with classical HL diagnosed between mid-1988 and 1997 in the Greater San Francisco Bay Area, with archived biopsy specimens assayed for EBV with immunohistochemistry and in situ hybridization. Vital status was followed through December 30, 2003 (median follow-up time, 97 months). Overall and disease-specific survival were analyzed with the Kaplan-Meier method and Cox proportional hazards regression models. Results: In children less than 15 years old, EBV presence was suggestively associated (P = .07) with favorable survival. In adults aged 15 to 44 years, EBV did not affect HL outcome, although a protective effect was suggested. In older adults (45 to 96 years), EBV presence nearly doubled the risk of overall and HL-specific mortality but only for patients with nodular sclerosis (NS) histologic subtype (hazard ratio for death = 2.5; 95% CI, 1.5 to 4.3). Conclusion: In HL, EBV tumor cell presence is associated with better survival in young patients and poorer survival in older patients with NS, independent of other factors. Variation in outcome by age and histology could indicate biologically distinct disease entities. Evidence that EBV is a meaningful prognostic marker may have therapeutic relevance.

Original languageEnglish (US)
Pages (from-to)7604-7613
Number of pages10
JournalJournal of Clinical Oncology
Volume23
Issue number30
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Human Herpesvirus 4
Hodgkin Disease
Survival
Population
Sclerosis
San Francisco
Age Factors
Proportional Hazards Models
In Situ Hybridization
Histology
Immunohistochemistry
Biopsy
Mortality
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Keegan, T. H., Glaser, S. L., Clarke, C. A., Gulley, M. L., Craig, F. E., DiGiuseppe, J. A., ... Ambinder, R. F. (2005). Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study. Journal of Clinical Oncology, 23(30), 7604-7613. https://doi.org/10.1200/JCO.2005.02.6310

Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma : A population-based study. / Keegan, Theresa H; Glaser, Sally L.; Clarke, Christina A.; Gulley, Margaret L.; Craig, Fiona E.; DiGiuseppe, Joseph A.; Dorfman, Ronald F.; Mann, Risa B.; Ambinder, Richard F.

In: Journal of Clinical Oncology, Vol. 23, No. 30, 2005, p. 7604-7613.

Research output: Contribution to journalArticle

Keegan, TH, Glaser, SL, Clarke, CA, Gulley, ML, Craig, FE, DiGiuseppe, JA, Dorfman, RF, Mann, RB & Ambinder, RF 2005, 'Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study', Journal of Clinical Oncology, vol. 23, no. 30, pp. 7604-7613. https://doi.org/10.1200/JCO.2005.02.6310
Keegan, Theresa H ; Glaser, Sally L. ; Clarke, Christina A. ; Gulley, Margaret L. ; Craig, Fiona E. ; DiGiuseppe, Joseph A. ; Dorfman, Ronald F. ; Mann, Risa B. ; Ambinder, Richard F. / Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma : A population-based study. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 30. pp. 7604-7613.
@article{ad1ece1d87534f32aa6a0c1336ea46e4,
title = "Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study",
abstract = "Purpose: Epstein-Barr virus (EBV) in Hodgkin's lymphoma (HL) cells has been considered as a prognostic marker for this heterogeneous disease, but studies have yielded mixed findings, likely because of selected patient series and failure to acknowledge an effect of age on outcome. This study assessed survival after HL in a population-based cohort large enough to examine the joint effects of EBV with other factors including age, sex, and histologic subtype. Patients and Methods: Included were 922 patients with classical HL diagnosed between mid-1988 and 1997 in the Greater San Francisco Bay Area, with archived biopsy specimens assayed for EBV with immunohistochemistry and in situ hybridization. Vital status was followed through December 30, 2003 (median follow-up time, 97 months). Overall and disease-specific survival were analyzed with the Kaplan-Meier method and Cox proportional hazards regression models. Results: In children less than 15 years old, EBV presence was suggestively associated (P = .07) with favorable survival. In adults aged 15 to 44 years, EBV did not affect HL outcome, although a protective effect was suggested. In older adults (45 to 96 years), EBV presence nearly doubled the risk of overall and HL-specific mortality but only for patients with nodular sclerosis (NS) histologic subtype (hazard ratio for death = 2.5; 95{\%} CI, 1.5 to 4.3). Conclusion: In HL, EBV tumor cell presence is associated with better survival in young patients and poorer survival in older patients with NS, independent of other factors. Variation in outcome by age and histology could indicate biologically distinct disease entities. Evidence that EBV is a meaningful prognostic marker may have therapeutic relevance.",
author = "Keegan, {Theresa H} and Glaser, {Sally L.} and Clarke, {Christina A.} and Gulley, {Margaret L.} and Craig, {Fiona E.} and DiGiuseppe, {Joseph A.} and Dorfman, {Ronald F.} and Mann, {Risa B.} and Ambinder, {Richard F.}",
year = "2005",
doi = "10.1200/JCO.2005.02.6310",
language = "English (US)",
volume = "23",
pages = "7604--7613",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "30",

}

TY - JOUR

T1 - Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma

T2 - A population-based study

AU - Keegan, Theresa H

AU - Glaser, Sally L.

AU - Clarke, Christina A.

AU - Gulley, Margaret L.

AU - Craig, Fiona E.

AU - DiGiuseppe, Joseph A.

AU - Dorfman, Ronald F.

AU - Mann, Risa B.

AU - Ambinder, Richard F.

PY - 2005

Y1 - 2005

N2 - Purpose: Epstein-Barr virus (EBV) in Hodgkin's lymphoma (HL) cells has been considered as a prognostic marker for this heterogeneous disease, but studies have yielded mixed findings, likely because of selected patient series and failure to acknowledge an effect of age on outcome. This study assessed survival after HL in a population-based cohort large enough to examine the joint effects of EBV with other factors including age, sex, and histologic subtype. Patients and Methods: Included were 922 patients with classical HL diagnosed between mid-1988 and 1997 in the Greater San Francisco Bay Area, with archived biopsy specimens assayed for EBV with immunohistochemistry and in situ hybridization. Vital status was followed through December 30, 2003 (median follow-up time, 97 months). Overall and disease-specific survival were analyzed with the Kaplan-Meier method and Cox proportional hazards regression models. Results: In children less than 15 years old, EBV presence was suggestively associated (P = .07) with favorable survival. In adults aged 15 to 44 years, EBV did not affect HL outcome, although a protective effect was suggested. In older adults (45 to 96 years), EBV presence nearly doubled the risk of overall and HL-specific mortality but only for patients with nodular sclerosis (NS) histologic subtype (hazard ratio for death = 2.5; 95% CI, 1.5 to 4.3). Conclusion: In HL, EBV tumor cell presence is associated with better survival in young patients and poorer survival in older patients with NS, independent of other factors. Variation in outcome by age and histology could indicate biologically distinct disease entities. Evidence that EBV is a meaningful prognostic marker may have therapeutic relevance.

AB - Purpose: Epstein-Barr virus (EBV) in Hodgkin's lymphoma (HL) cells has been considered as a prognostic marker for this heterogeneous disease, but studies have yielded mixed findings, likely because of selected patient series and failure to acknowledge an effect of age on outcome. This study assessed survival after HL in a population-based cohort large enough to examine the joint effects of EBV with other factors including age, sex, and histologic subtype. Patients and Methods: Included were 922 patients with classical HL diagnosed between mid-1988 and 1997 in the Greater San Francisco Bay Area, with archived biopsy specimens assayed for EBV with immunohistochemistry and in situ hybridization. Vital status was followed through December 30, 2003 (median follow-up time, 97 months). Overall and disease-specific survival were analyzed with the Kaplan-Meier method and Cox proportional hazards regression models. Results: In children less than 15 years old, EBV presence was suggestively associated (P = .07) with favorable survival. In adults aged 15 to 44 years, EBV did not affect HL outcome, although a protective effect was suggested. In older adults (45 to 96 years), EBV presence nearly doubled the risk of overall and HL-specific mortality but only for patients with nodular sclerosis (NS) histologic subtype (hazard ratio for death = 2.5; 95% CI, 1.5 to 4.3). Conclusion: In HL, EBV tumor cell presence is associated with better survival in young patients and poorer survival in older patients with NS, independent of other factors. Variation in outcome by age and histology could indicate biologically distinct disease entities. Evidence that EBV is a meaningful prognostic marker may have therapeutic relevance.

UR - http://www.scopus.com/inward/record.url?scp=32544455019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544455019&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.02.6310

DO - 10.1200/JCO.2005.02.6310

M3 - Article

C2 - 16186595

AN - SCOPUS:32544455019

VL - 23

SP - 7604

EP - 7613

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 30

ER -